Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) EV/FCF
As of 5 November 2026, Exelixis, Inc. (EXEL) trades at a EV/FCF of 14.1×. Over the past ten years it has ranged from −10.2× (December 2015) to 62.2× (January 2018); the current reading is higher than 39% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 12.9× | (4.82%) |
| FY2024 | 13.5× | (65.32%) |
| FY2023 | 39.0× | 120.91% |
| FY2022 | 17.6× | 37.74% |
| FY2021 | 12.8× | (54.26%) |
| FY2020 | 28.0× | 219.84% |
| FY2019 | 8.8× | (35.27%) |
| FY2018 | 13.5× | (77.88%) |
| FY2017 | 61.2× | 280.95% |
| FY2016 | 16.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 11.8× | 6.83% |
| Jun 2026 | 11.1× | (2.89%) |
| Mar 2026 | 11.4× | (11.37%) |
| Dec 2025 | 12.9× | (5.35%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | −39.7× |
| INSM Insmed, Inc. compare | −37.2× |
| SMMT Summit Therapeutics PLC compare | −23.1× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| EXEL Exelixis, Inc. | 14.1× |
| HALO Halozyme Therapeutics, Inc. compare | 18.4× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 22.9× |
| JAZZ Jazz Pharmaceuticals PLC compare | 26.2× |
| ASND Ascendis Pharma A/S compare | 41.1× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement